Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.59 |
| ▸ | HTR2A | P28223 | 11/20 | 0.59 |
| ▸ | HTR1A | P08908 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.59 |
| ▸ | DRD1 | P21728 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | DRD5 | P21918 | 2/20 | 0.59 |
| ▸ | HTR1D | P28221 | 2/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328526 | 0.90 | DRD2 (0.66) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| SCHEMBL8324484 | 0.89 | DRD2 (0.59) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| SCHEMBL8327642 | 0.89 | DRD2 (0.59) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| SCHEMBL8319486 | 0.89 | DRD2 (0.59) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| Ocaperidone SCHEMBL122321 | 0.87 | DRD2 (0.66) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| Ocaperidone SCHEMBL29710913 | 0.87 | DRD2 (0.66) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| SCHEMBL1430466 | 0.86 | DRD2 (0.65) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL7298070 | 0.85 | DRD2 (0.62) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| SCHEMBL7299513 | 0.85 | DRD2 (0.65) | DRD2HTR2AHTR1AKCNH2HRH3 | |
| SCHEMBL7298917 | 0.85 | DRD2 (0.63) | DRD2HTR2AHTR1AKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242269-B2 | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes | CIPLA LIMITED (IN) | 2012-08-14 | — | — | US | disclosed |
| US-8242269-B2 | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes | CIPLA LIMITED (IN) | 2012-08-14 | — | — | US | disclosed |
| US-20100298565-A1 | Processes for the Preparation of Paliperidone and Pharmaceutically Acceptable Salts Thereof and Intermediates for Use in the Processes | CIPLA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298565-A1 | Processes for the Preparation of Paliperidone and Pharmaceutically Acceptable Salts Thereof and Intermediates for Use in the Processes | CIPLA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2009047499-A2 | PROCESSES FOR THE PREPARATION OF PALIPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES FOR USE IN THE PROCESSES | CIPLA LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298565-A1 | Processes for the Preparation of Paliperidone and Pharmaceutically Acceptable Salts Thereof and Intermediates for Use in the Processes | AVPR2, AVPR1B, AVPR1A | DRD2 1043/4885HTR2A 1103/4885HTR1A 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.